Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Goedele De Smedt

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
International Clinical Psychopharmacology|April 23, 2004
Schizophrenia and osteoporosisMike Lean, Goedele De Smedt
The American Journal of Psychiatry|November 27, 2002
Relationship between premorbid functioning and symptom severity as assessed at first episode of psychosisJonathan Rabinowitz, Goedele De Smedt, Philip D Harvey, et al.
Journal of Child and Adolescent Psychopharmacology|May 25, 2005
Pharmacotherapy of disruptive behavior and item changes on a standardized rating scale: pooled analysis of risperidone effects in children with subaverage IQMichael Aman, Jan Buitelaar, Goedele De Smedt, et al.
The American Journal of Psychiatry|August 3, 2002
Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligenceMichael G Aman, Goedele De Smedt, Albert Derivan, et al.
Schizophrenia Research|November 5, 2002
Cross-national cognitive assessment in schizophrenia clinical trials: a feasibility studyPhilip D Harvey, Lidia Artiola i Fortuny, Estelle Vester-Blockland, et al.
AIDS Research and Human Retroviruses|July 14, 2010
A review of the safety and tolerability profile of the next-generation NNRTI etravirineBeatriz Grinsztejn, Giovanni Di Perri, William Towner, et al.
The Journal of Clinical Psychiatry|December 9, 2003
Prolactin levels during long-term risperidone treatment in children and adolescentsRobert L Findling, Vivek Kusumakar, Denis Daneman, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|December 21, 2004
Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patientsJan Croonenberghs, Joerg M Fegert, Robert L Findling, et al.
Clinical Pharmacokinetics|September 4, 2009
Clinical pharmacokinetics and pharmacodynamics of etravirineMonika Schöller-Gyüre, Thomas N Kakuda, Araz Raoof, et al.
Current HIV Research|October 16, 2010
Etravirine in the treatment of HIV-1: a clinical overview for healthcare professionalsPatrick Yeni, Anthony Mills, Monika Peeters, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
International Clinical Psychopharmacology|April 23, 2004
Schizophrenia and osteoporosisMike Lean, Goedele De Smedt
The American Journal of Psychiatry|November 27, 2002
Relationship between premorbid functioning and symptom severity as assessed at first episode of psychosisJonathan Rabinowitz, Goedele De Smedt, Philip D Harvey, et al.
Journal of Child and Adolescent Psychopharmacology|May 25, 2005
Pharmacotherapy of disruptive behavior and item changes on a standardized rating scale: pooled analysis of risperidone effects in children with subaverage IQMichael Aman, Jan Buitelaar, Goedele De Smedt, et al.
The American Journal of Psychiatry|August 3, 2002
Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligenceMichael G Aman, Goedele De Smedt, Albert Derivan, et al.
Schizophrenia Research|November 5, 2002
Cross-national cognitive assessment in schizophrenia clinical trials: a feasibility studyPhilip D Harvey, Lidia Artiola i Fortuny, Estelle Vester-Blockland, et al.
AIDS Research and Human Retroviruses|July 14, 2010
A review of the safety and tolerability profile of the next-generation NNRTI etravirineBeatriz Grinsztejn, Giovanni Di Perri, William Towner, et al.
The Journal of Clinical Psychiatry|December 9, 2003
Prolactin levels during long-term risperidone treatment in children and adolescentsRobert L Findling, Vivek Kusumakar, Denis Daneman, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|December 21, 2004
Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patientsJan Croonenberghs, Joerg M Fegert, Robert L Findling, et al.
Clinical Pharmacokinetics|September 4, 2009
Clinical pharmacokinetics and pharmacodynamics of etravirineMonika Schöller-Gyüre, Thomas N Kakuda, Araz Raoof, et al.
Current HIV Research|October 16, 2010
Etravirine in the treatment of HIV-1: a clinical overview for healthcare professionalsPatrick Yeni, Anthony Mills, Monika Peeters, et al.
Pageof 4